Donate Now
Home | News | Events | Press | Contact  

About UseNewsletterMessage BoardsAction CenterAdvocateWalk to End Alzheimer’sShopDonate

Find your chapter:

search by state

In My Community
Mount Sinai Clinical Trials
Text Size controlsNormal font sizeMedium font sizeLarge font size

Nerve Growth Factor (NGF) Study (GCO #09-0367) 

Mount Sinai researchers will be participating in a phase 2 clinical trial that is being conducted nationwide. This study will evaluate whether a type of gene therapy technique is safe, well-tolerated, and of benefit to people with Alzheimer’s Disease (AD). In this clinical trial, a study drug named CERE-110 will be injected into an area of the brain affected by AD so that the body can make nerve growth factor (NGF). NGF is a naturally occurring protein that may increase the survival of neurons that die in AD. In this study, half of the participants will receive CERE-110 via neurosurgery and the other half will receive a placebo procedure. Participation will also include a medical examination and cognitive testing. All participants will be carefully monitored by a team of physicians for two years. In addition, all participants will be asked if they want to participate in a separate, open-ended protocol for further clinical observation. This study is open to eligible individuals with mild AD between the ages 55 and 80, who are in good general health, and are able to undergo surgery. If you would like information about this study, please contact Priyanka Ghosh at 212-659-8885 or priyanka.

Neuroimaging in Head Injury and Cognitive Decline

This is a study investigating brain and memory and thinking problems associated with having a history of concussion or mild traumatic brain injury (TBI) in a sample of individuals between the ages of 35 and 60. We are investigating whether having a history of concussion or mild TBI with and without mild cognitive impairment (MCI) is distinct by using MRI and tests of memory and thinking. We are looking for participants with either a history of concussion/mild TBI and MCI or a history of TBI without MCI. Participants must be English speakers. Participants will receive compensation for their time. For more information, please contact 212-241-5290. MSSM #10-0954; Principle Investigator: Effie M. Mitsis, PhD MSSM approved through 1/24/13. 

Alzheimer’s Disease Neuroimaging Initiative – Grand Opportunity (ADNI-GO) 

In this study, we hope to determine whether imaging of the brain through MRI, PET and amyloid imaging scans can help predict and monitor the onset and progression of Alzheimer’s disease. In addition to neuroimaging, the study will collect and test blood and cerebral spinal fluid to determine if biomarkers can predict and monitor the disease. This study is sponsored by the National Institutes of Health and will take place at about 50 major universities across the US and Canada. No study drug is used in this research. Participants cannot be involved in other clinical trials while in this study. This is a longitudinal study which will span several years. We are looking for volunteers who can participate for the full duration. The study needs volunteers who: are between 55 and 90 years of age, in good health but have memory problems and concerns, are fluent in English or Spanish, are willing and able to undergo the test procedures, and have a study partner – a friend or relative who can accompany the volunteer to all clinic visits. Participant’s health will be closely monitored by a team of doctors and nurses. Participants will receive compensation for their time and costs incurred for travel, parking and meals. For more information, please contact Aliza Romirowsky at 212-241-1514. MSSM #10-0329; Principal Investigator: Hillel Grossman, M.D. MSSM approved through 3/29/12. Mount


Alzheimer's Association

Our vision is a world without Alzheimer's
Formed in 1980, the Alzheimer's Association is the world's leading voluntary health organization in Alzheimer's care, support and research.